Founded in 2007, NGM took a broad approach to its drug research, assembling a pipeline that spans from solid tumors to retinal diseases to liver and metabolic disorders.
NGM raised a few hundred million dollars in private funding before going public in the spring of 2019. Shares of the company, initially sold for $16, ticked up in value over the following year and a half, to trade at just north of $31 by the end of 2020.
